B of A Securities Upgrades Maravai LifeSciences to Buy, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Michael Ryskin has upgraded Maravai LifeSciences (NASDAQ:MRVI) from Neutral to Buy, while also lowering the price target from $10 to $8.
December 12, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maravai LifeSciences has been upgraded by B of A Securities from Neutral to Buy, although the price target has been reduced from $10 to $8.
The upgrade to Buy suggests a positive outlook on the stock by the analyst, which could lead to increased investor confidence and potential stock price appreciation in the short term. However, the reduction in the price target may temper some of the positive sentiment, as it implies a lower expected future price than previously estimated.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100